Reaction
Tumour Pseudoprogression reporting signals
As of the last recalculation, Tumour Pseudoprogression appears in 1,072 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is TEMOZOLOMIDE (PRR 207.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Temozolomide | 186 | 207.2 | 209.0 |
| Pembrolizumab | 464 | 150.2 | 150.9 |
| Pemetrexed | 50 | 47.4 | 47.6 |
| Nivolumab | 188 | 45.6 | 45.7 |
| Ipilimumab | 82 | 39.9 | 39.9 |
| Pemetrexed Disodium | 64 | 34.6 | 34.7 |
| Axicabtagene Ciloleucel | 16 | 31.9 | 32.0 |
| Amphotericin B | 13 | 20.4 | 20.4 |
| Atezolizumab | 34 | 17.5 | 17.5 |
| Durvalumab | 17 | 16.5 | 16.5 |
| Bendamustine Hcl | 13 | 16.5 | 16.5 |
| Carboplatin | 95 | 15.8 | 15.8 |
| Fludarabine Phosphate | 26 | 13.1 | 13.1 |
| Paclitaxel (Aibumin-Bound) | 51 | 12.6 | 12.6 |
| Paclitaxel | 57 | 11.7 | 11.8 |
| Cisplatin | 44 | 11.4 | 11.4 |
| Polatuzumab Vedotin | 5 | 10.0 | 10.0 |
| Axitinib | 9 | 9.0 | 9.0 |
| Gemcitabine | 17 | 8.5 | 8.5 |
| Gemcitabine Hydrochloride | 20 | 7.4 | 7.4 |
| Cetuximab | 11 | 6.9 | 6.9 |